Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.
Saved in:
| Title: | Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology. |
|---|---|
| Authors: | Schauer SP; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Toth B; Department of Data and Statistical Sciences, Immunology, Infectious Diseases, and Ophthalmology, Genentech Inc., South San Francisco, California, USA., Lee J; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Honigberg LA; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Ramakrishnan V; Department of Clinical Pharmacology, Modeling and Simulation, Development Sciences, Genentech Inc., South San Francisco, California, USA., Jiang J; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Kollmorgen G; Roche Diagnostics, GmbH, Penzberg, Germany., Bayfield A; Roche Diagnostics, GmbH, Penzberg, Germany., Wild N; Roche Diagnostics, GmbH, Penzberg, Germany., Hoffman J; Department of Translational Medicine, Operations Diagnostics Technology Innovation, Genentech Inc., South San Francisco, California, USA., Ceniceros R; Department of Early Clinical Development, Clinical Operations, Genentech Inc., South San Francisco, California, USA., Dolton M; Department of Clinical Pharmacology, Modeling and Simulation, Development Sciences, Genentech Inc., South San Francisco, California, USA., Bohórquez SMS; Department of Early Clinical Development, Clinical Imaging Group, Genentech Inc., South San Francisco, California, USA., Hoogenraad CC; Department of Neuroscience, Genentech Inc., South San Francisco, California, USA., Wildsmith KR; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Teng E; Department of Early Clinical Development, OMNI, Genentech Inc., South San Francisco, California, USA., Monteiro C; Department of Early Clinical Development, OMNI, Genentech Inc., South San Francisco, California, USA., Anania V; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA., Yeh FL; Department of Translational Medicine, OMNI, Genentech Inc., South San Francisco, California, USA. |
| Source: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Dec; Vol. 20 (12), pp. 8855-8866. Date of Electronic Publication: 2024 Nov 08. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1552-5279 |
|---|---|
| DOI: | 10.1002/alz.14346 |
